Key result
Catheter ablation improves hemodynamics and clinical outcomes over medical therapy in AF with HFpEF.
Why the study?
HFpEF and atrial fibrillation frequently coexist and worsen patient outcomes, and while catheter ablation has emerged as a potential treatment strategy, no large trials or clear guidelines exist for this population.
Does catheter ablation improve outcomes (mortality, hospitalization, hemodynamics, and recurrence) compared to medical treatment in patients with atrial fibrillation and heart failure with preserved ejection fraction?
Does catheter ablation improve outcomes (mortality, hospitalization, hemodynamics, and recurrence) compared to medical treatment in patients with atrial fibrillation and heart failure with preserved ejection fraction?
Current evidence suggests catheter ablation is promising and potentially superior to medical therapy for patients with coexisting atrial fibrillation and HFpEF, though definitive large-scale trial data are still needed.
Answers are grounded in this paper and cite their sources.
May support ablation consideration in AF-HFpEF; leaves open confirmation and practice change pending large RCTs.
Purpose of Review Heart failure with preserved ejection fraction and atrial fibrillation frequently coexist and are linked by shared mechanisms including atrial myopathy, elevated filling pressures, fibrosis, and adverse hemodynamic interactions. The combination of both diseases worsens patient outcomes, and catheter ablation has emerged as a potentially important treatment strategy in this population. This review aims to summarize and highlight the current evidence on ablation in patients with atrial fibrillation and HFpEF. Recent Findings When examining outcomes of mortality, hospitalization, hemodynamics, and recurrence, ablation appears to be superior to medical treatment with some mixed results. However, no large trials have been conducted on the topic, and no clear guidelines for ablation in HFpEF patients exist. Summary Ablation is promising but not yet definitive for patients with atrial fibrillation and HFpEF. Ongoing trials, including CASTLE-HFpEF should clarify the gaps including patient selection, procedural strategy, and outcome benefit.
No takes yet. Share an insight, caveat, or question.
Darzi et al. (2026) conducted a review in Atrial fibrillation and heart failure with preserved ejection fraction (HFpEF). Catheter ablation for atrial fibrillation vs. Medical therapy / usual care was evaluated. Catheter ablation appears superior to medical therapy for improving hemodynamics, quality of life, and clinical outcomes in AF-HFpEF, though definitive large randomized trials are still ongoing.
Synapse has enriched 10 related papers. Consider them for comparative context: